Posted by Michael Wonder on 29 Mar 2020
Infinity receives fast track designation for IPI-549 in combination with the checkpoint inhibitor Opdivo for the treatment of advanced urothelial cancer
25 March 2020 - Infinity Pharmaceuticals announced today that the U.S. FDA has granted fast track designation for IPI-549 in combination with nivolumab (Opdivo) for the treatment of advanced urothelial cancer.
Infinity is currently enrolling patients in MARIO-275, the company’s ongoing global, randomised, controlled Phase 2 study in collaboration with Bristol Myers Squibb, to evaluate IPI-549 in combination with Opdivo in platinum-refractory, I/O naïve patients with advanced urothelial cancer.
